Answers are grounded in this paper and cite their sources.
To investigate the efficacy, safety and pharmacokinetics/pharmacodynamics of risdiplam in infants with genetically diagnosed presymptomatic spinal muscular atrophy (SMA).
No takes yet. Share an insight, caveat, or question.
Finkel et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: